Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes
- PMID: 12231378
- DOI: 10.1016/s0014-2999(02)02191-x
Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes
Abstract
The pyrazolopyrimidine zaleplon is a hypnotic agent that acts at the benzodiazepine recognition site of GABA(A) receptors. Zaleplon, like the hypnotic agent zolpidem but unlike classical benzodiazepines, exhibits preferential affinity for type I benzodiazepine (BZ(1)/omega(1)) receptors in binding assays. The modulatory action of zaleplon at GABA(A) receptors has now been compared with those of zolpidem and the triazolobenzodiazepine triazolam. Zaleplon potentiated GABA-evoked Cl(-) currents in Xenopus oocytes expressing human GABA(A) receptor subunits with a potency that was higher at alpha1beta2gamma2 receptors than at alpha2- or alpha3-containing receptors. Zolpidem, but not triazolam, also exhibited selectivity for alpha1-containing receptors. However, the potency of zaleplon at these various receptors was one-third to one-half that of zolpidem. Zaleplon and zolpidem also differed in their actions at receptors containing the alpha5 or gamma3 subunit. Zaleplon, zolpidem, and triazolam exhibited similar patterns of efficacy among the different receptor subtypes. The affinities of zaleplon for [(3)H]flunitrazepam or t-[(35)S]butylbicyclophosphorothionate ([(35)S]TBPS) binding sites in rat brain membranes were lower than those of zolpidem or triazolam. Furthermore, zaleplon, unlike zolpidem, exhibited virtually no affinity for the peripheral type of benzodiazepine receptor.
Similar articles
-
Modulation of [35S]TBPS binding by ligands with preferential affinity for benzodiazepine BZ1 sites in the cerebral cortex of newborn and adult rats.Eur J Pharmacol. 1995 Jun 23;290(1):37-47. doi: 10.1016/0922-4106(95)90014-4. Eur J Pharmacol. 1995. PMID: 7664823
-
Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor.J Pharmacol Exp Ther. 2004 Nov;311(2):537-46. doi: 10.1124/jpet.104.071282. Epub 2004 Jul 15. J Pharmacol Exp Ther. 2004. PMID: 15256540
-
Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors.Biochem Pharmacol. 2018 Dec;158:339-358. doi: 10.1016/j.bcp.2018.08.019. Epub 2018 Aug 17. Biochem Pharmacol. 2018. PMID: 30121248
-
Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.Clin Pharmacokinet. 2004;43(4):227-38. doi: 10.2165/00003088-200443040-00002. Clin Pharmacokinet. 2004. PMID: 15005637 Review.
-
New insights into the mechanism of action of hypnotics.J Psychopharmacol. 1999;13(4 Suppl 1):S11-20. doi: 10.1177/026988119901304S03. J Psychopharmacol. 1999. PMID: 10667451 Review.
Cited by
-
Developing, validating, and comparing an analytical method to simultaneously detect z-drugs in urine samples using the QuEChERS approach with both liquid chromatography and gas chromatography-tandem mass spectrometry.Saudi Pharm J. 2024 Feb;32(2):101950. doi: 10.1016/j.jsps.2023.101950. Epub 2024 Jan 2. Saudi Pharm J. 2024. PMID: 38288131 Free PMC article.
-
Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review.Front Neurosci. 2022 Jul 29;16:893015. doi: 10.3389/fnins.2022.893015. eCollection 2022. Front Neurosci. 2022. PMID: 35968380 Free PMC article. Review.
-
Duration of treatment and activation of α1-containing GABAA receptors variably affect the level of anxiety and seizure susceptibility after diazepam withdrawal in rats.Brain Res Bull. 2014 May;104:1-6. doi: 10.1016/j.brainresbull.2014.03.002. Epub 2014 Mar 30. Brain Res Bull. 2014. PMID: 24695241 Free PMC article.
-
An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists.Adv Pharmacol Sci. 2012;2012:134523. doi: 10.1155/2012/134523. Epub 2012 Jan 29. Adv Pharmacol Sci. 2012. PMID: 22363345 Free PMC article.
-
Zolpidem is a potent stoichiometry-selective modulator of α1β3 GABAA receptors: evidence of a novel benzodiazepine site in the α1-α1 interface.Sci Rep. 2016 Jun 27;6:28674. doi: 10.1038/srep28674. Sci Rep. 2016. PMID: 27346730 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources